Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Brief: Oncolytics Biotech and Adlai Nortye enter into $86.6 mln regional licensing agreement for Reolysin

Nov 16 (Reuters) - Oncolytics Biotech Inc  ONC.TO  
    * Oncolytics Biotech Inc. and Adlai Nortye enter into $86.6 
million regional licensing agreement for Reolysin 
    * Oncolytics Biotech Inc - Oncolytics to receive upfront, 
licensing fee and milestone payments to support phase 3 
registration study of usd $21.2 million 
    * Oncolytics Biotech - Co is eligible to receive up to 
additional 
$65.4 million upon achievement of clinical, regulatory, 
commercialization milestones 
    * Oncolytics Biotech Inc - Upon Adlai Nortye's 
commercialization 
of reolysin, Oncolytics is eligible to receive double digit 
royalty payments 
    * Oncolytics - Adlai to have exclusive development, 
commercialization rights to Reolysin in China, Hong Kong, Macau, 
Singapore, South Korea and Taiwan 
 
Source text for Eikon:  ID:nPn78H3mpa  
Further company coverage:  ONC.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com;))

Recent news on Oncolytics Biotech

See all news